The combination of strong top-line growth, margin expansion, and clinical trial progress suggests improving commercial traction; monitor the final Q1 results in mid-May for confirmation and any updates on BENEFIT-HF enrollment pace.
Price Chart
Executive Summary
CVRx reported preliminary Q1 2026 revenue of $14.7–14.8 million (approximately 20% YoY growth) and raised gross margin guidance to 87%, while also announcing the first site activation in its pivotal BENEFIT-HF trial. These developments reflect accelerating commercial execution and progress toward expanding its addressable market.
Key Financial Metrics
Key Facts
- Preliminary Q1 2026 revenue expected in the range of $14.7–14.8 million, up ~20% YoY from $12.3 million
- Gross margin expected at ~87%, up from 84% in Q1 2025
- U.S. active implanting centers increased to 257 as of March 31, 2026, up from 252 at year-end 2025
- First site activated in the BENEFIT-HF trial, a pivotal study that could triple the company’s addressable market
- Cash and cash equivalents were approximately $72.3 million as of March 31, 2026
Financial Impact
Revenue growth of ~20% YoY and gross margin expansion to 87% indicate strong commercial momentum and improving unit economics
Risk Factors
- Preliminary financial results are subject to change upon final audit
- BENEFIT-HF trial success is uncertain and will require significant time and capital investment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-042354 |
| Document: tm2611335d1_ex99-1.htm | 0001104659-26-042354 |
| Document: 0001104659-26-042354-index-headers.html | 0001104659-26-042354 |
| Document: 0001104659-26-042354-index.html | 0001104659-26-042354 |
| Document: 0001104659-26-042354.txt | 0001104659-26-042354 |
| 8-K Data (Synthetic) | 0001104659-26-042354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | Press Release | $1.37 | awaiting T+5 | — | $1.38 (+1.09%) |
Oct 2, 2026 23d ago | SC 13D/A | $1.56 $1.48 | ▲ +5.13% | ▲ +5.55% | $1.38 (+11.22%) |
Aug 11, 2026 10w ago | 8-K | $2.60 $2.75 | ▼ −5.77% | ▼ −6.17% | $1.38 (+46.73%) |
Jul 23, 2026 13w ago | Press Release | $4.74 $5.38 | ▲ +13.50% | ▲ +13.13% | $1.38 (−70.78%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.03 $4.95 | ▼ −1.59% | ▼ −2.26% | $1.38 (−72.47%) |
Jun 9, 2026 19w ago | 8-K | $5.20 $4.98 | ▼ −4.23% | ▼ −6.64% | $1.38 (−73.37%) |
Jun 9, 2026 19w ago | Press Release | $5.20 $4.98 | ▼ −4.23% | ▼ −6.64% | $1.38 (−73.37%) |
Jun 3, 2026 20w ago | 3 | $5.88 $4.89 | ▼ −16.84% | ▼ −14.28% | $1.38 (−76.45%) |
May 11, 2026 23w ago | 8-K | $5.27 $5.94 | ▲ +12.71% | ▲ +12.64% | $1.38 (−73.72%) |
Apr 27, 2026 25w ago | Press Release | $7.48 $7.80 | ▲ +4.21% | ▲ +2.52% | $1.38 (−81.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers